<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471870</url>
  </required_header>
  <id_info>
    <org_study_id>DFIDM-1801</org_study_id>
    <nct_id>NCT04471870</nct_id>
  </id_info>
  <brief_title>ARCANGELO (itAlian pRospective Study on CANGrELOr)</brief_title>
  <acronym>ARCANGELO</acronym>
  <official_title>Multicentre Observational, Prospective Cohort Study Including Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Who Receive Cangrelor i.v. Transitioning to Clopidogrel, Prasugrel or Ticagrelor Per os</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sponsor implemented a post-authorisation safety study (PASS), category 3, focused in&#xD;
      Acute Coronary Syndrome, in order to collect information about the safety of cangrelor in the&#xD;
      real clinical practice, evaluating the safety of the transition to all the oral P2Y12&#xD;
      inhibitors (cangrelor, ticagrelor and prasugrel).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of any haemorrages according to BARC (Bleeding Academic Research Consortium) criteria</measure>
    <time_frame>30 days post-PCI</time_frame>
    <description>The incidence will be calculated as the ratio between the number of patients experiencing at least one event during the 30-day observation period over the total number of evaluable patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of type 1-2 (mild) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria</measure>
    <time_frame>48 hours after PCI</time_frame>
    <description>The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of type 1-2 (mild) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria</measure>
    <time_frame>30 days after PCI</time_frame>
    <description>The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patientsConsortium [BARC]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of type 3-5 (moderate severe) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria</measure>
    <time_frame>48 hours after PCI</time_frame>
    <description>The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patientsConsortium [BARC]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of type 3-5 (moderate severe) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria</measure>
    <time_frame>30 days after PCI</time_frame>
    <description>The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patientsConsortium [BARC] bleedings, according to the Bleeding Academic Research Consortium [BARC]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major adverse cardiac events (MACE)</measure>
    <time_frame>48 hours after PCI</time_frame>
    <description>The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patients. MACE will comprise any of the following events: death, myocardial infarction (MI), ischemia-driven revascularisation (IDR) and stent thrombosis (ST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major adverse cardiac events (MACE)</measure>
    <time_frame>30 days after PCI</time_frame>
    <description>The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patients. MACE will comprise any of the following events: death, myocardial infarction (MI), ischemia-driven revascularisation (IDR) and stent thrombosis (ST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the type of oral platelet P2Y12 receptor (prasugrel/ticagrelor/clopidogrel)</measure>
    <time_frame>30 days after PCI</time_frame>
    <description>It will be calculated the proportion of patients receiving an oral platelet P2Y12 receptor in terms of type (prasugrel/ticagrelor/clopidogrel) and timing of administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the use of glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors</measure>
    <time_frame>30 days after PCI</time_frame>
    <description>It will be calculated the proportion of patients receiving GPIIb/IIIa inhibitors</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute coronary syndromes undergoing percutaneous coronary intervention who&#xD;
        receive cangrelor i.v. according to the clinical practice&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients' written informed and privacy consent obtained before or at the end of the&#xD;
             PCI procedure according to patients' condition but in any case, prior to collection of&#xD;
             any study-related data;&#xD;
&#xD;
          2. Male or female patients aged ≥ 18 years;&#xD;
&#xD;
          3. Patients with acute coronary syndromes undergoing PCI;&#xD;
&#xD;
          4. Patients who are planned to be treated with cangrelor, or who have received treatment&#xD;
             with cangrelor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with active bleeding or increased risk of bleeding, because of impaired&#xD;
             haemostasis and/or irreversible coagulation disorders or due to recent major&#xD;
             surgery/trauma or uncontrolled severe hypertension;&#xD;
&#xD;
          2. Patients with history of stroke or transient ischaemic attack (TIA);&#xD;
&#xD;
          3. Patients with hypersensitivity to the active substance (cangrelor) or to any of its&#xD;
             excipients;&#xD;
&#xD;
          4. Known pregnancy or breast-feeding female patients;&#xD;
&#xD;
          5. Patients with stable angina (SA).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Info</last_name>
    <phone>0521 2791</phone>
    <phone_ext>+39</phone_ext>
    <email>clinicaltrials_info@chiesi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>A.O.U. Riuniti</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisa Nicolini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Donato</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Bolognese</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Consorziale Policlinico</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martino Pepe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bassiano</name>
      <address>
        <city>Bassano del Grappa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Chirillo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Pio</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marino Scherillo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valerio Lanzilotti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Maffeo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Sant'Anna e San Sebastiano</name>
      <address>
        <city>Caserta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Calabrò</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico-Vittorio Emanuele P.O. Ferrarotto</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corrado Tamburino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale SS Annunziata</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Caporale</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASO Santa Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberta Rossini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Di Mario</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Fabrizio Spaziani</name>
      <address>
        <city>Frosinone</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Menichelli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Andrea</name>
      <address>
        <city>La Spezia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Menozzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Goretti</name>
      <address>
        <city>Latina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Versaci</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana &quot;G. Monasterio&quot; Ospedale del Cuore G. Pasquinucci</name>
      <address>
        <city>Massa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Berti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Galli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. A. Cardarelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ciro Mauro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Plinio Cirillo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Ferlini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi</name>
      <address>
        <city>Rivoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Rolfo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo De Luca, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aurelia Hospital</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrizio Tomai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Trani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Sassari</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Parodi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto I</name>
      <address>
        <city>Siracusa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Contarini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Mauriziano</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Musumeci</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simone Muraglia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca' Foncello</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Cernetti</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Real-word</keyword>
  <keyword>ACS</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

